Skip to main content
Top
Published in: Pathology & Oncology Research 3/2008

01-09-2008 | Original Paper

Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature

Authors: D. A. Morgenstern, H. Rees, N. J. Sebire, J. Shipley, John Anderson

Published in: Pathology & Oncology Research | Issue 3/2008

Login to get access

Abstract

Myogenin immunostaining has been described as a useful marker of the alveolar subtype of rhabdomyosarcoma and as a tool for distinguishing it from the more common embryonal subtype. To add to the growing body of literature describing this phenomenon we analysed myogenin immunohistochemical staining in 152 tumors using a rhabdomyosarcoma tissue array. Results were analysed blinded to histological type by two independent investigators. Samples were excluded if any samples failed to stain with desmin and/or myogenin. Mean percentage of myogenin positive cells was significantly greater for ARMS (n = 31; mean percentage positivity 59% (95% confidence intervals ± 7%) than ERMS (n = 41, mean percentage positivity 16%, 95% confidence intervals ± 4; P < 0.0001). This data is consistent with previously published studies identifying strong nuclear myogenin staining in a high proportion of cells as a marker of alveolar histology.
Literature
1.
go back to reference McManus AP, O'Reilly MA, Jones KP, Gusterson BA, Mitchell CD, Pinkerton CR, Shipley JM (1996) Interphase fluorescence in situ hybridization detection of t(2;13)(q35;q14) in alveolar rhabdomyosarcoma–a diagnostic tool in minimally invasive biopsies. J Pathol 178:410–414CrossRefPubMed McManus AP, O'Reilly MA, Jones KP, Gusterson BA, Mitchell CD, Pinkerton CR, Shipley JM (1996) Interphase fluorescence in situ hybridization detection of t(2;13)(q35;q14) in alveolar rhabdomyosarcoma–a diagnostic tool in minimally invasive biopsies. J Pathol 178:410–414CrossRefPubMed
2.
go back to reference Sapi Z, Antal I, Papai Z, Szendroi M, Mayer A, Jakab K, Pajor L, Bodo M (2002) Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques. Diagn Cytopathol 26:232–242CrossRefPubMed Sapi Z, Antal I, Papai Z, Szendroi M, Mayer A, Jakab K, Pajor L, Bodo M (2002) Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques. Diagn Cytopathol 26:232–242CrossRefPubMed
3.
go back to reference Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K (2001) Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 85:831–835CrossRefPubMed Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K (2001) Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 85:831–835CrossRefPubMed
4.
go back to reference Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20:2672–2679CrossRefPubMed Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20:2672–2679CrossRefPubMed
5.
go back to reference Sebire NJ, Malone M (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56:412–416CrossRefPubMed Sebire NJ, Malone M (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol 56:412–416CrossRefPubMed
6.
go back to reference Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24:816–822CrossRefPubMed Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24:816–822CrossRefPubMed
7.
go back to reference Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, Coffin CM (2001) Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25:1150–1157CrossRefPubMed Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, Coffin CM (2001) Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25:1150–1157CrossRefPubMed
8.
go back to reference Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM (1995) Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 147:1799–1810PubMed Wang NP, Marx J, McNutt MA, Rutledge JC, Gown AM (1995) Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 147:1799–1810PubMed
9.
go back to reference Folpe AL (2002) MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Pathol 9:198–203CrossRefPubMed Folpe AL (2002) MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Pathol 9:198–203CrossRefPubMed
10.
go back to reference Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M (2000) Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 13:988–993CrossRefPubMed Kumar S, Perlman E, Harris CA, Raffeld M, Tsokos M (2000) Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 13:988–993CrossRefPubMed
11.
go back to reference Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, Lussan C, Longavenne E, Bui NB, Delattre O, Coindre JM (2004) Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101:2817–2824CrossRefPubMed Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, Lussan C, Longavenne E, Bui NB, Delattre O, Coindre JM (2004) Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101:2817–2824CrossRefPubMed
12.
go back to reference Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, Parham D, Qualman S, Houghton P (2000) Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156:399–408PubMed Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, Parham D, Qualman S, Houghton P (2000) Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156:399–408PubMed
13.
go back to reference Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ (2006) An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 30:962–968CrossRefPubMed Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ (2006) An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 30:962–968CrossRefPubMed
14.
go back to reference Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed
Metadata
Title
Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature
Authors
D. A. Morgenstern
H. Rees
N. J. Sebire
J. Shipley
John Anderson
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9012-5

Other articles of this Issue 3/2008

Pathology & Oncology Research 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine